Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) - results of the UKCCSG 9003 protocol
1998

Improved Cure Rate in Children with B-cell Acute Lymphoblastic Leukaemia and Stage IV B-cell Non-Hodgkin's Lymphoma

Sample size: 63 publication Evidence: moderate

Author Information

Author(s): A Atra, M Gerrard, R Hobson, JD lmeson, S Ashley, CR Pinkerton

Primary Institution: The Royal Marsden Hospital NHS Trust/Institute of Cancer Research

Hypothesis

Can a short, intensive multiagent chemotherapy regimen improve outcomes for children with B-ALL and B-NHL?

Conclusion

The study confirms that the UKCCSG 9003 protocol is effective, achieving a 69% survival rate in children with B-ALL and B-NHL.

Supporting Evidence

  • 43 patients (69%) survived in complete remission after treatment.
  • 10 patients (16%) relapsed after achieving complete remission.
  • Seven patients (11%) died of treatment-related toxicity.

Takeaway

This study shows that a special treatment can help many kids with serious blood cancers get better.

Methodology

Patients were treated with a short, intensive multiagent chemotherapy regimen based on the French LMB 86 regimen.

Limitations

The study had a small sample size and a notable rate of toxic deaths.

Participant Demographics

Patients were aged 11 months to 16.5 years, with a median age of 8.4 years; 55 were boys.

Statistical Information

Confidence Interval

55-79%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication